Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with W­­H­I­M Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

References